Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium

Neurourology and Urodynamics

Volumn 34, Issue 1, 2015, Pages 79-84

  Hanna Mitchell, Ann T ^a   Wolf Johnston, Amanda S ^a   Barrick, Stacey R ^a   Kanai, Anthony J ^a   Chancellor, Michael B ^b   De Groat, William C ^a   Birder, Lori A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

bladder mucosa; exocytosis; SNAP 23; SNAP 25

Indexed keywords

ADENOSINE TRIPHOSPHATE; BOTULINUM TOXIN A; GLYCOPROTEIN; SYNAPTIC VESICLE GLYCOPROTEIN 2A; SYNAPTIC VESICLE GLYCOPROTEIN 2B; SYNAPTIC VESICLE GLYCOPROTEIN 2C; SYNAPTOSOMAL ASSOCIATED PROTEIN 23; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG; ACETYLCHOLINE RELEASE INHIBITOR; MEMBRANE PROTEIN; NERVE PROTEIN; SNAP23 PROTEIN, RAT; SNAP25 PROTEIN, RAT; SV2A PROTEIN, RAT; VESICULAR TRANSPORT PROTEIN;

ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER MUCOSA; CATALYSIS; ENZYME RELEASE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UROTHELIUM; ANIMAL; CELL CULTURE; DRUG EFFECTS; METABOLISM; MUSCLE CONTRACTION; SMOOTH MUSCLE; URINARY BLADDER, OVERACTIVE;

ACETYLCHOLINE RELEASE INHIBITORS; ADENOSINE TRIPHOSPHATE; ANIMALS; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; HUMANS; MEMBRANE GLYCOPROTEINS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NERVE TISSUE PROTEINS; RATS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; UROTHELIUM; VESICULAR TRANSPORT PROTEINS;

EID: 84916927942     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22508     Document Type: Article

References (42)

1. Chancellor MB, Fowler CJ, Apostolidis A, et al. Drug insight: Biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008; 5: 319-28.
2. Dowson C, Khan MS, Dasgupta P, et al. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol 2010; 7: 661-7.
3. Apostolidis A, Popat R, Yiangou Y,. Decreased sensory receptors P2 × 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005; 174: 977-82.
4. Ikeda Y, Zabbarova IV, Birder LA, et al. Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. Eur Urol 2012; 62: 1157-64.
5. Birder LA, de Groat WC,. Mechanisms of disease: Involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007; 4: 46-54.
6. Smith CP, Chancellor MB,. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004; 171: 2128-37.
7. Smith CP, Gangitano DA, Munoz A, et al. Botulinum toxin type A normalized alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 2008; 52: 1068-75.
8. Coelho A, Dinis P, Pinto R, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2010; 57: 884-90.
9. Chopra B, Barrick SR, Meyers S, et al. Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium. J Physiol 2005; 562: 859-71.
10. Birder LA, Wolf-Johnston AS, Sun Y, et al. Alteration in TRPV1 and muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol 2013; 207: 123-9.
11. Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol 2009; 56: 159-66.
12. Datta SN, Roosen A, Pullen A, et al. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive bladders, and changes with botulinum neurotoxin administration. J Urol 2010; 184: 2578-85.
13. Yokoyama T, Chancellor MB, Ogama K, et al. Botulinum toxin type A for the treatment of lower urinary tract disorders. Int J Urol 2012; 19: 202-15.
14. Nitti VW, Dmochowski R, Herschorn S, et al. Onabotulinum toxin A for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3 randomized placebo-controlled trial. J Urol 2013; 189: 2186-93.
15. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2012; 58: 360-5.
16. Takahashi R, Yunoki T, Naoto S, et al. Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats. J Urol 2012; 188: 1993-9.
17. Mahrhold S, Rummel A, Bigalke H, et al. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 2006; 580: 2011-4.
18. Born M, Pahner I, Hilger-Ahnert G, et al. The maintenance of the permeability barrier of bladder facet cells requires a continuous fusion of discoid vesicles with the apical plasma membrane. Eur J Cell Biol 2003; 82: 343-50.
19. Braun J, Madison DV,. A novel SNAP-25-caveolin complex correlates with the onset of persistent synaptic potentiation. J Neurosci 2000; 20: 5997-6006.
20. Honer WG, Falkai P, Bayer TA, et al. Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cerebral Cortex 2002; 12: 549-56.
21. Lucioni A, Bales GT, Lotan TL, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008; 101: 366-70.
22. Smith CP, Franks ME, McNeil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169: 1896-900.
23. Mika J, Rojewska E, Makuch W, et al. The effect of botulinum neurotoxin A on sciatic nerve injury-induced neuroimmunological changes in rat dorsal root ganglia and spinal cord. Neuroscience 2011; 175: 358-66.
24. Kiris E, Nuss JE, Burnett JC, et al. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res 2001; 6: 195-205.
25. Ford AP,. In pursuit of P2 × 3 antagonists: Novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal 2012; 8: S3-S26.
26. Prakasam HS, Herrington H, Roppolo JR, et al. Modulation of bladder function by luminal adenosine turnover and A1 receptor activation. Am J Physiol 2012; 303: F279-292.
27. Yu W, Khanderwal P, Apodaca G,. Distinct apical and basolateral membrane requirements for stretch-induced membrane traffic at the apical surface of bladder umbrella cells. Mol Biol Cell 2009; 20: 282-95.
28. Khanderwal P, Ruiz WG, Apodaca G,. Compensatory endocytosis in bladder umbrella cells occurs through an integrin-regulated and RhoA- and dynamin-dependent pathway. EMBO J 2010; 29: 1961-75.
29. Wang EC, Lee JM, Ruiz WG, et al. ATP and purinergic receptor-dependent membrane traffic in bladder umbrella cells. J Clin Invest 2005; 115: 2412-22.
30. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-6.
31. Haferkamp A, Schurch B, Reitz A, et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004; 46: 784-91.
32. Kessler TM, Khan S, Panicker JN, et al. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: Preliminary results. Eur Urol 2010; 57: 879-83.
33. Matak I, Riederer P, Lackovic Z,. Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int 2012; 61: 236-9.
34. Restani L, Novelli E, Bottari D, et al. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic 2012; 13: 1083-9.
35. Maksymowych AB, Simpson LL,. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharm Exp Ther 2004; 310: 633-41.
36. Sadoul K, Lang J, Montecucco C, et al. SNAP-25 is expressed in islets of langerhans and is involved in insulin release. J Cell Biol 1995; 128: 1019-28.
37. Schulte-Baukloh H, Zurawski TH, Knispel HH, et al. Persistence of the synaptosomal-associated protein-25 cleavage product after intradetrusor botulinum toxin A injections in patients with myelomeningocele showing an inadequate response to treatment. BJU Int 2007; 100: 1075-80.
38. +-ATPase in cultured inner medullary collecting duct cells. Am J Physiol Cell Physiol 2001; 280: C775-781.
39. 2+. Mol Biol Cell 2004; 15: 1928-30.
40. Petrou SP, Parker AS, Crook JE, et al. Botulinum A toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: A phase 1/2 study. Mayo Clin Proc 2009; 84: 702-6.
41. Chuang Y-C, Tyagi P, Huang C-C, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009; 182: 786-92.
42. O'Connor V, Lee AG,. Synaptic vesicle fusion and synaptotagmin: 2B or not 2B ? Nat Neurosci 2002; 5: 823-4.